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Abstract: Current chemotherapy drugs for pancreatic cancer only offer an increase in survival of
up to six months. Additionally, they are highly toxic to normal tissues, drastically affecting the
quality of life of patients. Therefore, the search for novel agents, which induce apoptosis in cancer
cells while displaying limited toxicity towards normal cells, is paramount. The olive biophenols,
oleuropein, hydroxytyrosol and tyrosol, have displayed cytotoxicity towards cancer cells without
affecting non-tumorigenic cells in cancers of the breast and prostate. However, their activity in
pancreatic cancer has not been investigated. Therefore, the aim of this study was to determine the
anti-pancreatic cancer potential of oleuropein, hydroxytyrosol and tyrosol. Pancreatic cancer cells
(MIA PaCa-2, BxPC-3, and CFPAC-1) and non-tumorigenic pancreas cells (HPDE) were treated
with oleuropein, hydroxytyrosol and tyrosol to determine their effect on cell viability. Oleuropein
displayed selective toxicity towards MIA PaCa-2 cells and hydroxytyrosol towards MIA PaCa-2 and
HPDE cells. Subsequent analysis of Bcl-2 family proteins and caspase 3/7 activation determined that
oleuropein and hydroxytyrosol induced apoptosis in MIA PaCa-2 cells, while oleuropein displayed a
protective effect on HPDE cells. Gene expression analysis revealed putative mechanisms of action,
which suggested that c-Jun and c-Fos are involved in oleuropein and hydroxytyrosol induced
apoptosis of MIA PaCa-2 cells.
Keywords: olive; phenolic compound; nutraceutical; chemoprevention; anti-cancer; MIA PaCa-2;
HPDE; oleuropein; hydroxytyrosol
1. Introduction
Adherence to a Mediterranean diet is associated with a reduced risk for heart disease and most
cancers, including pancreatic cancer [1–4]. One of the major differences between Mediterranean diets
and other healthy diets is the high intake of olives and olive oil; the annual intake of olive oil in
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Mediterranean countries can range 15.3–23 kg per capita [5,6]. Many of the health benefits associated
with consuming olive oil have been attributed to its high concentration of biophenols [5].
Oleuropein is a major biophenol for olive products (olives, olive oil and olive leaves). However,
oleuropein is often degraded during the processing of olives to olive oil, hence, the concentration of
oleuropein in extracts from olive products will vary. Regardless, oleuropein can reach up to 14% of
the dry weight of olives and olive oil can contain up to 2.8 mg/kg. In addition, olive leaf extracts can
contain up to 61.56 g/kg [7–12].
Hydroxytyrosol is one of the most potent antioxidants in olive oil. Hydroxytyrosol and tyrosol
are degradation products of oleuropein both in the olive fruit and in the body (Figure 1). Hydrolysis of
oleuropein occurs in the fruit during maturation and processing [13] and after ingestion of oleuropein,
it is broken down by lipase activity and converted to hydroxytyrosol [14]. The hydroxytyrosol and
tyrosol content of olive products can also vary. Interestingly, the hydrolysis of oleuropein during olive
oil processing often results in higher concentrations of hydroxytyrosol present in olive oil compared to
olives [7,15].
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The activity of oleuropein and hydroxytyrosol in vitro has been well characterised for certain 
cancers. For example, oleuropein has induced apoptosis in colon cancer and breast cancer cells via 
activation of the p53 pathway [16,17]. Additionally, oleuropein inhibited the proliferation and 
induced thiol modifications, γ-glutamylcysteine synthetase and reactive oxygen species in prostate 
cancer cells [18]. Oleuropein has also activated apoptosis in hepatocellular carcinoma cells by 
suppression of the phosphatidylinositol 3-kinase/protein kinase B pathway [19]. In addition, 
hydroxytyrosol has demonstrated a range of activities in vitro. Hydroxytyrosol treatment of 
leukaemia cells resulted in the induction of apoptosis while not affecting primary human cells, 
including lymphocytes and polymorphonuclear cells [20], highlighting the chemo-preventative 
potential of hydroxytyrosol. Hydroxytyrosol treatment of vascular endothelial cells resulted in an 
upregulation of PI3K/Akt and Erk 1/2 and the subsequent activation of the Nrf-2 pathway exhibiting 
cardio-protective effects [21]. 
Oleuropein and hydroxytyrosol have also exhibited anti-cancer activity in vivo. Oleuropein 
treatment in combination with doxorubicin significantly reduced tumour volume of breast cancer 
xenografts [22] and melanoma tumour volumes [23] in mice and prevented ultraviolet B 
radiation-induced carcinogenesis in nude mice at a dose of 25 mg/kg/day [24]. Hydroxytyrosol 
exhibited anti-inflammatory properties in mice at a dose of 5 mg/kg [25] and inhibited the growth of 
cholangiocarcinoma xenografts in mice after a dose of 250 mg/kg/day [26]. Moreover, a dose of 20 
mg/kg of hydroxytyrosol significantly inhibited tumour growth, angiogenesis and the activation of 
the AKT and NF-κB pathways in an orthotopic model of human hepatocellular carcinoma in nude 
mice [27]. 
Pancreatic cancer is a devastating disease with a five-year survival rate of less that 8%. 
Resistance to conventional treatment options and the toxicity of current chemotherapy agents, such 
as gemcitabine, makes pancreatic cancer a vital target for the development of novel therapeutic 
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The activity of oleuropein and hydroxytyrosol in vitro has been well characterised for certain
cancers. For example, oleuropein has induced apoptosis in colon cancer and breast cancer cells via
activation of the p53 pathway [16,17]. Additionally, oleuropein inhibited the proliferation and induced
thiol modifications, γ-glutamylcysteine synthetase and reactive oxygen species in prostate cancer
cells [18]. Oleuropein has also activated apoptosis in hepatocellular carcinoma cells by suppression
of the phosphatidylinositol 3-kinase/protein kinase B pathway [19]. In addition, hydroxytyrosol has
demonstrated a range of activities in vitro. Hydroxytyrosol treatment of leukaemia cells resulted
in the induction of apoptosis while not affecting primary human cells, including lymphocytes
and polymorphonuclear cells [20], highlighting the chemo-preventative potential of hydroxytyrosol.
Hydroxytyrosol treatment of vascular endothelial cells resulted in an upregulation of PI3K/Akt and
Erk 1/2 and the subsequent activation of the Nrf-2 pathway exhibiting cardio-protective effects [21].
Oleuropein and hydroxytyrosol have also exhibited anti-cancer activity in vivo. Oleuropein
treatment in combination with doxorubicin significantly reduced tumour volume of breast
cancer xenografts [22] and melanoma tumour volumes [23] in mice and prevented ultraviolet B
radiation-induced carcinogenesis in nude mice at a dose of 25 mg/kg/day [24]. Hydroxytyrosol
exhibited anti-inflammatory properties in ice at a dose of 5 g/kg [25] and inhibited the growth of
cholangiocarcinoma xenografts in mice after a dose of 250 mg/kg/day [26]. Moreover, a dose of 20
mg/kg of hydroxytyrosol significantly inhibited tumour growth, angiogenesis and the activation of the
AKT and NF-κB pathways in an orthotopic model of human epatocellular carcinoma in ude mice [27].
Pancreatic cancer is a devastating disease with a five-year survival rate of less that 8%. Resistance
to conve tional tre tment options nd the toxicity of current chemotherapy agents, such as gemcitabine,
make pancreatic ca cer vital target for the development of novel therapeutic agents [28]. While
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oleuropein and hydroxytyrosol have been explored as anti-cancer agents for different tissues, their
activity in pancreatic cancer has yet not been determined. Considering the link between adherence to
a Mediterranean diet and reduced pancreatic cancer risk [29], the anti-pancreatic cancer potential of
oleuropein and hydroxytyrosol warrants investigation.
We have previously shown that olive leaf extracts, containing high concentrations of oleuropein,
reduced the viability of pancreatic cancer cells (MIA PaCa2) in a dose dependant manner [10].
However, crude extracts are a complex mixture of compounds and it was not possible to determine the
compound/s responsible for the observed effects. Considering the desperate need for new treatments
for pancreatic cancer, the potential exhibited by olive biophenols and our previous observations,
the aim of this study was to investigate the effects of the major olive biophenols, oleuropein and
hydroxytyrosol, on pancreatic cancer cells in vitro.
2. Results
2.1. Treatment with Olive Biophenols Reduces Pancreatic Cancer Cell Viability
The viability of pancreas cancer (MIA PaCa-2, BxPC-3 and CFPAC-1) and non-tumorigenic
pancreas (HPDE) cells treated with oleuropein, hydroxytyrosol or tyrosol was assessed using a CCK8
viability assay to determine effective doses for each drug. Neither oleuropein nor hydroxytyrosol had
any effect on the viability of BxPC-3 or CFPAC-1 cells (Table 1) in the treatment range tested (0–300
µM). However, both compounds dose dependently inhibited the proliferation of MIA PaCa-2 cells; the
IC50 for oleuropein and hydroxytyrosol were 150.1 µM and 75.1 µM, respectively (Table 1).
Table 1. Viability of pancreatic cancer cells (MIA PaCa-2, BxPC-3, CFPAC-1 and ASPC-1) and
non-tumorigenic pancreas cells (HPDE) when treated with 0–300 µM of oleuropein, hydroxytyrosol or
tyrosol. Values represent concentration required to achieve a 50% reduction in viability (IC50).
Cell Line Oleuropein (µM) Hydroxytyrosol (µM) Tyrosol (µM) Gemcitabine (nM)
MIA PaCa-2 150.1 75.1 >300 31.02
BxPC-3 >300 >300 >300 3.6
CFPAC-1 >300 >300 >300 2.6
ASPC-1 >300 >300 >300 12
HPDE >300 65.5 >300 0.04
In contrast to its effects on MIA PaCa-2 cells, oleuropein did not reduce the viability of HPDE
cells, even at the concentration of 300 µM (Table 1). Considering the usual sensitivity of HPDE cells
to cytotoxic drugs (Gemcitabine, IC50 = 0.04 nM), the activity of oleuropein and hydroxytyrosol was
investigated further. However, tyrosol did not have any influence on the viability of any of the
pancreatic cells within the treatment range tested (Table 1) and, hence, the activity of tyrosol was not
explored further.
2.2. Oleuropein and Hydroxytyrosol Induce Morphological Changes in Pancreatic Cells
Significant morphological changes were observed following treatment with oleuropein and
hydroxytyrosol (Figure 2). Cell shrinkage and the formation of apoptotic bodies were identified in
MIA PaCa-2 cells treated with oleuropein or hydroxytyrosol and hydroxytyrosol treatment of HPDE
cells also caused similar effects. Importantly, oleuropein did not induce any morphological changes in
HPDE cells when compared to vehicle control (Figure 2).
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Figure 3. Cell cycle analysis of MIA PaCa-2 (A) and HPDE (B) cells treated with oleuropein (200 µM)
and hydroxytyrosol (100 µM) for 24 h. Bar graphs show the percentage of cells in G0/1, S and G2 phase
of the cell cycle measured by MUSE cell cycle analysis kit. A representative DNA content profile for
vehicle control, oleuropein and hydroxytyrosol (HT) treatment is pictured for MIA PaCa-2 (A) and
HPDE (B) cells. Ordinary two-way ANOVA and Tukey’s multiple comparisons test compare the
percentage of treated cells (oleuropein or hydroxytyrosol) in each stage of the cell cycle to vehicle
control. **** p < 0.0001.
In HPDE cells, oleuropein did not have a significant effect (Figure 3B) on the number of cells in
G0/1 or G2 phase (p = 0.058 and 0.3088, respectively). However, hydroxytyrosol treatment of HPDE
cells caused a significant increase in in the percentage of cells in G2 (7.3% increase, p < 0.0001) and a
decrease in the percentage of cells in G0/1 (11.8% decrease, p < 0.0001) compared to vehicle control
(Figure 3B). Importantly, this effect was much smaller than that observed for MIA PaCa-2 cells.
2.4. Treatment with Oleuropein and Hydroxytyrosol Promotes Caspase 3/7 Dependent Apoptosis
Caspase 3 and 7 are activated downstream in the apoptosis cascade and result in the cleavage
of protein substrates and the disassembly of the cell [30]. Therefore, the activation of caspase 3/7
measured by fluorescent tagging and subsequent flow cytometry was used to determine the induction
of apoptosis. In cells expressing caspase 3/7, the fluorescent dye (MUSE caspase 3/7 reagent) was
able to bind to the DNA, while the dead cell marker (7-AAD) entered membrane-compromised,
later-stage apoptotic and dead cells. The number of fluorescently labelled cells expressing caspase
3/7 was counted by MUSE flow cytometry. Treatment of MIA PaCa-2 cells with either oleuropein or
hydroxytyrosol caused a significant increase in the percentage of cells expressing activated caspase
3/7 (Figure 4A) with the total percentage of cells (early + late apoptosis) increasing from 7.93%
(vehicle control) to 40.63% after oleuropein treatment (p < 0.0001) and 47.17% after hydroxytyrosol
treatment (p < 0.0001). The effect on HPDE cells was much smaller, with the total percentage of HPDE
cells with caspase 3/7 activation only increasing from 4.6% (vehicle control) to 10% after oleuropein
(p = 0.613) and 22.01% after hydroxytyrosol (p < 0.0001) treatment (Figure 4B).
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Figure 4. Induction of caspase 3/7-dependent apoptosis of MIA PaCa-2 (A) and HPDE (B) cells treated
with oleuropein (200 µM) and hydroxytyrosol (100 µM) for 48 h. Bar graphs show the percentage of
live, early apoptotic, late apoptotic and dead cells determined by analysis of the activation of caspase
3/7. Ordinary two-way ANOVA and Tukey’s multiple comparisons test compare total apoptotic cells
in treated cells (oleuropein or hydroxytyrosol) to vehicle control. **** p < 0.0001.
2.5. Differential Expression of Bcl2 Family Proteins Following Treatment with Oleuropein and Hydroxytyrosol
The Bcl-2 family of proteins are involved in the regulation of apoptosis [31]. To determine if Bcl-2
family members were involved in oleuropein-induced apoptosis, the expression of Bax, Bak and Bcl-2
were determined using gel electrophoresis and Western blotting. Results were normalised to GAPDH
expression and expressed as fold change compared to vehicle control cells. Interestingly, expression
of the pro-apoptotic protein Bax, decreased in MIA PaCa-2 cells (Figure 5A) after oleuropein and
hydroxytyrosol treatment (23.4% and 26.6% decrease, p = 0.035 and 0.017, respectively). Expression of
the anti-apoptotic protein Bcl-2 also decreased (51.4% and 33.7% decrease, p < 0.0001 and 0.0027,
respectively). However, there was no significant change (Figure 5A) in the expression of Bak
(oleuropein p = 0.302 and hydroxytyrosol p = 0.105). Additionally, oleuropein or hydroxytyrosol
treatment of HPDE cells significantly decreased the expression of Bax (31.5% and 20.3% decrease,
p = 0.016 and 0.013, respectively) and Bak (25.6% and 29.5% decrease, p = 0.052 and 0.024, respectively)
while increasing the expression of Bcl-2 (28.9% and 69.2% increase, p = 0.027 and <0.0001, respectively)
(Figure 5B).
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cells. For (A,B), ordinary two-way ANOVA with Tukey’s multiple comparisons test compares 
protein expression of treated cells (oleuropein or hydroxytyrosol) to vehicle control; for (C,D), 
ordinary one-way ANOVA with Tukey’s multiple comparisons test compares Bax/Bcl-2 ratio of 
treated cells to vehicle control. * p 0.05, ** p 0.01, *** p 0.001, **** p < 0.0001. 
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different compared to controls (control = 2.5, hydroxytyrosol = 2.7, p = 0.72) (Figure 5C). 
Interestingly, in HPDE cells treated with either oleuropein or hydroxytyrosol, the Bax/Bcl-2 ratio 
was more than halved (control = 1.02, oleuropein = 0.55, p = 0.012 and hydroxytyrosol = 0.47, p = 
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Figure 5. Expression of Bax, Bak and Bcl-2 in MIA PaCa-2 (A) and HPDE (B) cells treated with
oleuropein (200 µM) and hydroxytyrosol (HT) (100 µM) or vehicle control as assessed using gel
electrophoresis and estern blotting. GAPDH was used as a loading control. Results displayed
as optical density measurements of target antibody/GAPDH/control average; hence, results are
represented as fold change. Ratio of the expression of Bax to Bcl-2 in MIA PaCa-2 (C) and HPDE ( ) cells.
For (A,B), ordinary two-way ANOV with Tukey’s multiple comparisons test compares protein
expression of treated cells (oleuropein or hydroxytyrosol) to vehicle control; for (C,D), ordinary one-way
ANOVA with Tukey’s multiple comparisons test compares Bax/Bcl-2 ratio of treated cells to vehicle
control. * p 0.05, ** p 0.01, *** p 0.001, **** p < 0.0001.
A more important indicator of survivability, than the individual expression levels of each apoptosis
protein, is the ratio of Bax to Bcl-2 expression. The Bax/Bcl-2 ratio in MIA PaCa-2 cells treated with
oleuropein was almost double that of vehicle control cells (control = 2.5, oleuropein = 4.3, p = 0.007)
(Figure 5C). For hydroxytyrosol-treated cells the Bax/Bcl-2 ratio was not significant different compared
to controls (control = 2.5, hydroxytyrosol = 2.7, p = 0.72) (Figure 5C). Interestingly, in HPDE cells treated
with either oleuropein or hydroxytyrosol, the Bax/Bcl-2 ratio was more than halved (control = 1.02,
oleuropein = 0.55, p = 0.012 and hydroxytyrosol = 0.47, p = 0.0063) (Figure 5D). These data suggest
that oleuropein may have induced apoptosis in MIA PaCa-2 cells via the regulation of the expression
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of mitochondrial proteins while oleuropein and hydroxytyrosol may have had a protective effect on
HPDE cells.
2.6. Gene and Protein Expression Changes in MIA PaCa-2 Cells Following Treatment with Oleuropein
and Hydroxytyrosol
To gain a better understanding of the mechanism by which oleuropein and hydroxytyrosol induce
apoptosis in MIA PaCa-2 cells, and the protective role of oleuropein in HPDE cells, the changes in gene
expression were determined. An mRNA microarray was utilised to determine the changes in gene
expression after treatment with oleuropein or hydroxytyrosol (Table 2). Genes with significant, high
fold changes that have a known role in pancreatic cancer were selected for further validation at the
protein level by using gel electrophoresis and Western blotting.
Table 2. Fold change in the gene expression of JUN, FOS and EGR-1 in pancreatic cancer cells
(MIA PaCa-2) and ADAMTS1 in non-tumorigenic cells (HPDE) when treated with oleuropein
or hydroxytyrosol.
Cell Line GeneSymbol Treatment
Fold Change (Linear)
(VS. Control)
ANOVA p-Value
(VS. Control)
MIA PaCa-2
JUN
Oleuropein 4.64 0.000126
Hydroxytyrosol 4.68 0.000041
FOS
Oleuropein 2.41 0.007736
Hydroxytyrosol 4.98 0.000103
EGR-1
Oleuropein 8.01 0.00083
Hydroxytyrosol 20.75 0.000019
HPDE
ADAMTS1 Oleuropein −2.19 0.00003
Hydroxytyrosol - -
Studies suggest that Early Growth Response-1 (EGR-1) is a cancer suppressor gene and
accordingly, it was found that EGR-1 was significantly upregulated in oleuropein (8-fold, p = 0.018)
and hydroxytyrosol (20-fold, p = 0.018) treated MIA PaCa-2 cells (Table 2). Considering EGR-1 has
previously been shown to induce apoptosis in pancreatic cancer [32], EGR-1 was chosen for further
validation at the protein level to determine if this change in gene expression resulted in a functional
effect. However, despite the increased expression observed in the microarray (Table 2), this was not
reflected at the protein level (Figure 6A). In fact, the protein expression of EGR-1 was significantly
reduced after treatment with oleuropein (55% decrease p = 0.006) and hydroxytyrosol (50% decrease,
p = 0.008).
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JUN and FOS are known proto-oncogenes which dimerize to form the transcription factor AP-1.
More specifically, forced expressi n of c-Jun and c-Fos has previously b en linked t the induction
of apo tosis in pancr atic cancer cells in vitro [33]. In the present study (Table 2), the expressi n
of JUN ignificantly in reased 4.6-fold after oleuropein treatment (p = 0.000126) and 4.7-fold after
hydroxytyrosol tr tment (p = 0.000041). The ex ression of FOS also increased 2.4-fol after oleuropein
treatment (p = 0.007736) and 5-fold after hydroxytyrosol treatment (p = 0.000103) (Table 2). Due to the
relati nship between c-Jun and c-Fos, and apoptosis in pancreatic cancer cells, the effects on c-Jun and
c-Fos were determined at the prot i level. The protein expressi n f c-Jun increased in both ol uropein
(291% increase, p = 0.008) and hydroxytyrosol-treated c lls (242% increase, p = 0.029) (Figure 6C).
This tr nd was also observed with c-Fos; c-Fos protein expression increased in MIA P Ca-2 cells treated
with oleuropein (289% increase, p = 0.0002) and hydroxytyrosol (182% increase, p = 0.015) (Figure 6B).
2.7. Reduced Expression of ADAMTS1 in HPDE Cells Following Treatment with Oleuropein
Expression of ADAMTS1 has been positively correlated with disease progression in cancers of
different origins [34]. The gene expression of ADAMTS1 in HPDE cells after treatment with oleuropein
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was reduced 2.2-fold (p = 0.00003) (Figure 6D). Therefore, to gain an insight into the potential protective
role of oleuropein in HPDE cells, ADAMTS1 was validated at the protein level. The protein expression
of ADAMTS1 was also significantly reduced in cells treated with oleuropein (50% decrease, p = 0.003)
(Figure 6D). However, the effect of hydroxytyrosol on the expression of ADAMTS1 by HPDE cells was
not statistically significant (26% decrease, p = 0.055) (Figure 6).
3. Discussion
The epidemiological link between the Mediterranean diet and pancreatic cancer [29] offers a
potential avenue for the exploration of biophenols which may possess anti-pancreatic cancer potential.
Oleuropein and hydroxytyrosol are biophenols found in olives, olive leaves and olive oil and their
consumption has been linked to health benefits [35,36]. Additionally, the anti-cancer potential of
oleuropein and hydroxytyrosol has been described in cancers of several different origins [16,17,37];
however, the present study is the first to investigate their activity in pancreatic cancer.
Oleuropein treatment reduced the viability of pancreatic cancer cells (MIA PaCa-2) but the
viability of non-tumorigenic cells (HPDE) was not affected, augmenting oleuropein’s potential as a
chemotherapeutic agent for pancreatic cancer. Oleuropein has previously displayed similar effects
towards prostate cells by reducing the proliferation of prostate cancer cells while displaying an
antioxidant effect on non-malignant prostate cells [18]. The authors attributed this selectivity to the
sensitivity of cancer cells to ROS generation. Many human cancer cell types exist in a highly oxidative
state compared to their normal tissues and, therefore, the selective activity of oleuropein on MIA
PaCa-2 cells could be due to their increased sensitivity towards ROS. Moreover, hydroxytyrosol is a
more potent antioxidant than oleuropein [38], potentially explaining the lower IC50 of hydroxytyrosol
in MIA PaCa-2 cells compared to oleuropein.
Changes in the cell cycle are often an early indicator of cellular stress leading to apoptosis.
In the present study, treatment of MIA PaCa-2 cells with oleuropein or hydroxytyrosol caused cell
cycle arrest at G2 phase of the cell cycle. Oleuropein has been shown to cause cell cycle arrest in
neuroblastoma cells by down-regulation of Cylin-D1/2 and 3, and CDK4 and 6 while up-regulating
p53 [39]. Hydroxytyrosol has also previously caused cell cycle arrest in prostate cancer cells by
inhibiting cyclin-D1/E and CDK2/4 and inducing inhibitory p21/p27 [40]. Therefore, oleuropein and
hydroxytyrosol may be exerting cell cycle arrest via changing the expression of specific cyclins and
CDKs involved in G2/M phase. However, this was not investigated in the present study.
Resistance to chemotherapy occurs primarily due to cellular evasion of apoptosis. This evasion
can lead to deregulated cell proliferation and subsequent tumour formation. Therefore, the induction
of tumour cell apoptosis without displaying toxicity towards surrounding normal cells is an effective
chemotherapy strategy [41]. In the present study, the concentrations of oleuropein required to
achieve a reduction in viability of pancreatic cancer cells were quite high for a biological context
(Table 1). Nevertheless, these data are useful to determine the appropriate dose of oleuropein for
in vivo models of pancreatic cancer. Additionally, it is important to understand how drugs behave
in vitro as cellular toxicity can arise via several mechanisms. For these reasons, the ability of oleuropein
and hydroxytyrosol to induce apoptosis was determined.
The Bcl-2 family of proteins regulate apoptotic mitochondrial events, such as, the ability of
ceramide to form channels in the mitochondrial outer membrane. Anti-apoptotic proteins (Bcl-2)
inhibit ceramide channels while the pro-apoptotic proteins (Bax and Bak) enhance these channels and
lead to the release of pro-apoptotic proteins into the cytosol, which initiates the execution phase of
apoptosis [42]. For this reason, the Bax/Bcl-2 ratio is an important indicator of cell survivability. In this
study, the treatment of MIA PaCa-2 cells with oleuropein or hydroxytyrosol increased the Bax/Bcl-2
ratio, followed by caspase 3/7-dependent apoptosis. In contrast, Bax/Bcl-2 decreased in HPDE cells
after treatment with olive biophenols. These results demonstrate the selective activity of oleuropein
and hydroxytyrosol in pancreatic cells.
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Olive biophenols have previously been shown to induce apoptosis in cancer cells. Oleuropein
treatment has caused an increase in the Bax/Bcl-2 ratio in lung cancer cells (A549) [43], breast cancer
cells [44] and neuroblastoma cells (SH-SY5Y) [39], in each case activating the caspase cascade causing
cells to undergo apoptosis. Similarly, hydroxytyrosol has previously increased the Bax/Bcl-2 ratio in
prostate cancer cells [40]. The previous studies credit varying upstream mechanisms for the change in
expression of Bcl-2 family proteins, which appear to be cell type specific.
To elucidate the mechanisms underlying the selective activity of oleuropein and hydroxytyrosol,
changes in gene expression after treatment were assessed using microarrays. Major genes differentially
expressed in MIA PaCa-2 cells after treatment include EGR-1, JUN and FOS. EGR-1 has been linked
with apoptosis in MIA PaCa-2 cells treated with vitamin E δ-tocotrienol by causing an increase
in the Bax/Bcl-2 ratio and subsequent caspase cascade inducing apoptosis [32]. In the present
study, oleuropein and hydroxytyrosol treatment also increased the gene expression of EGR-1 and
the Bax/Bcl-2 ratio as well as caspase 3/7 activation in MIA PaCa-2 cells. However, EGR-1 protein
expression decreased as a result of treatment with oleuropein and hydroxytyrosol; therefore, the
role of EGR-1 in oleuropein and hydroxytyrosol-induced apoptosis of MIA PaCa-2 cells is still to
be determined.
The proteins c-Jun and c-Fos dimerize to form Activator Protein-1 (AP-1). The AP-1 site is
a ubiquitous regulatory element that is found in a wide range of promoter and enhancer regions.
They bind to AP-1 DNA recognition elements and control cell proliferation, transformation, survival
and death. The functions of Fos-Jun family proteins depend on the specific cell type in which they are
expressed [45,46]. We found that oleuropein and hydroxytyrosol treatment of MIA PaCa-2 cells caused
an increase in the gene expression of JUN and FOS and an increase in the protein expression of c-Jun
and c-Fos. Previously, the forced expression of c-Jun and c-Fos has induced apoptosis in neuronal
cells [47,48]. Additionally, treatment of myelodysplastic cells with the plant-derived compound,
withaferin A, caused an increase in the mRNA expression of JUN and FOS and their subsequent
protein expression and resulted in downstream activation of apoptosis [49]. More specifically, Ren et
al. [33] were able to show that increasing the expression of c-Jun and c-Fos in MIA PaCa-2 cells caused
the downstream induction of apoptosis via activation of Bim and the subsequent effect on Bcl-2 family
proteins. These previous studies support the theory that the induction of apoptosis in this study could
be due to an increased expression of c-Jun and c-Fos, which dimerize into AP-1 and result in activation
of the AP-1/JNK pathway. However, more work is needed to substantiate this hypothesis.
The effects observed in MIA PaCa-2 cells in the present study and the previous studies showcase
the ability of oleuropein and hydroxytyrosol to induce apoptosis via several different pathways.
However, in this study, oleuropein and hydroxytyrosol decreased the Bax/Bcl-2 ratio in HPDE cells,
suggesting a protective effect on these non-tumorigenic cells. In addition to their potent cytotoxic
activities previously described, these olive biophenols have also displayed cytoprotective effects.
Kalaiselvan et al. [50] found that oleuropein, hydroxytyrosol and even tyrosol exhibited a protective
effect on rat liver cells exposed to the harsh environmental toxin, 2,3,7,8-tetrachlorodibenzo-P-dioxin
(TCDD) by decreasing the Bax/Bcl-2 ratio. Additionally, olive oil treatment of hippocampus CA1
neurons following ischemia in mice also reduced apoptosis by decreasing Bax and increasing Bcl-2
expression [51]. The cytoprotective activity of oleuropein was also observed by Geyikoglu et al. [52],
who found that the administration of 200 mg/kg/day of oleuropein for 3 days modulated oxidative
stress and completely reversed 8-OHdg production in mouse kidneys after treatment with the
chemotherapy drug, cisplatin. These studies support the observed protective effects of oleuropein and
hydroxytyrosol in HPDE cells.
ADAMTS1 is a metalloprotease that remodels the ECM (extracellular matrix) through the
proteolytic degradation of key substrates such as collagen [53]. Low ADAMTS1 expression has been
linked to tumorigenesis in some cancers. However, the specific role of ADAMTS1 in pancreatic cancer is
yet to be determined. In the present study, lower levels of ADAMTS1 were expressed in oleuropein and
hydroxytyrosol-treated HPDE cells than in control cells. Low expression of ADAMTS1 in pancreatic
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cancer tissue compared to normal pancreas tissue has previously been studied [34]; however, large
variability in the data resulted in the relationship being non-significant (p = 0.206). Despite this, low
ADAMTS1 expression in primary tumours compared to normal tissue is a common trend that can
be correlated with disease progression. Reports on prostate [54], colon [55] and lung cancer [56]
have shown lower expression of ADAMTS1 in primary cancers compared to non-tumorigenic tissue.
Further investigations have revealed that epigenetic silencing through promoter hyper-methylation to
be the key mechanism underlying ADAMTS1 suppression during tumour development. Therefore, the
methylation state of ADAMTS1 has been proposed as a potential early biomarker for colon, prostate and
non-small cell lung cancer [56]. As mentioned, oleuropein treatment of the non-tumorigenic pancreas
cells (HPDE) decreased the expression of ADAMTS1 in the present study; this result conflicts the
protective activity exhibited by oleuropein. Moreover, considering the previous reports of ADAMTS1
and disease progression, it is possible that the observed protective effects of oleuropein on HPDE
cells could instead be the first stages of cellular transformation leading to tumorigenesis. However,
more research is needed to determine the role of oleuropein and hydroxytyrosol on ADAMTS1
functions as well as the role of ADAMTS1 on pancreatic cells and pancreatic cancer disease progression.
Due to the complex nature of tumorigenesis, these data highlight the importance of determining
chemo-preventative mechanisms.
For the first time, anti-pancreatic cancer properties of oleuropein and hydroxytyrosol have been
determined in vitro. Oleuropein and hydroxytyrosol arrested the cell cycle, increased the Bax/Bcl-2
ratio, increased activation of caspase 3/7 and induced apoptosis in pancreatic cancer cells (MIA PaCa-2).
Increased expression of c-Jun and c-Fos was also observed in oleuropein and hydroxytyrosol-treated
cells and, therefore, dimerization of c-Jun and c-Fos into AP1 is a potential underlying mechanism for
oleuropein and hydroxytyrosol-induced apoptosis in MIA PaCa-2 cells. However, more work is needed
to validate these findings. Additionally, oleuropein did not display toxicity towards non-tumorigenic
cells (HPDE); in fact, a putative protective effect was observed. However, the downregulation of
ADAMTS1 in oleuropein treated cells conflicts its protective label. Therefore, more work is also needed
to determine if the observed protective effects of oleuropein on non-tumorigenic pancreas cells could
lead to cancer prevention.
4. Materials and Methods
4.1. Materials
Oleuropein, hydroxytyrosol, tyrosol, isopropranol, glycogen, ethanol, 2-mercaptoethanol, and
Roche cOmplete protease inhibitor cocktail as well as the reagents for the RIPA lysis buffer (made from
150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate
(SDS) and 50 mM Tris-HCl, pH 8.0) were purchased from Sigma Aldrich (Temecula, MS, USA).
CCK-8 reagent was purchased from Dojindo Molecular Technologies Inc., (Rockville, MD, USA).
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-F12), Keratinocyte Serum-Free
Media (K-SFM), Roswell Park Memorial Institute medium (RPMI), Iscove’s Modified Dulbecco’s
Medium (IMDM), trypsin-EDTA, L-glutamine, phosphate buffered saline (PBS) and TRIzol reagent
were purchased from Invitrogen (Carlsbad, CA, USA). Foetal Bovine Serum (FBS) was purchased from
Interpath (Heildberg West, Australia). Luminata Classico western horse radish peroxidase substrate
and MUSE™ cell cycle and caspase 3/7 reagent kits were purchased from MERK-Millipore (Temecula,
MA, USA). Gene Chip WT PLUS reagent kits were purchased from Affymetrix (Carlsbad, CA, USA).
RIPA lysis buffer and bicinchoninic acid (BCA) protein assay kit was purchased from Thermofisher
(Mulgrave, Australia). Pancreatic cancer cells, MIA PaCa-2, CFPAC-1, BxPC-3 and ASPC-1, were
purchased from ATCC (Manassas, VA, USA) and immortalised normal pancreatic ductal epithelial
cells (HPDE) were a gift from the lab of Dr. M. Tsao (MD, FRCPC, University of Health Network,
Toronto, ON, Canada). All cell lines were authenticated by CellBank Australia (Westmead, Australia).
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4.2. Pancreas Cell Culture
Human pancreatic cancer cells, MIA PaCa2, were cultured in DMEM-F12, supplemented with
10% FBS, 2.5% horse serum and L-glutamine (100 µg/mL). BxPC-3 and ASPC-1 were cultured in
RPMI supplemented with 10% FBS and L-glutamine (100 µg/mL). CFPAC-1 cells were cultured in
IMDM supplemented with 10% FBS and L-glutamine (100 µg/mL). Human Pancreas (HPDE) cells
were cultured in K-SFM supplemented with BPE and EGF. All cells were grown and maintained at
37 ◦C under 5% CO2.
4.3. Assessment of Cell Growth Inhibition
Cell growth inhibition was determined using the Dojindo Cell Counting Kit-8. Cells were seeded
into a 96 well plate at 3000–10,000 cells per well and allowed to adhere for 24 h. Cells were then
treated within the range of 0–300 µM of each compound, 0–50 nM gemcitabine (positive control) or
0.5% DMSO (vehicle control). After 72 h, 10% CCK-8 solution in media was added before incubating at
37 ◦C for 180 min. The absorbance was measured at 450 nm and cell growth inhibition was determined
as the IC50. All experiments were performed in triplicate.
4.4. Apoptosis Assay
The induction of apoptosis was evaluated by assessing caspase 3/7 activation. MIA PaCa-2, and
HPDE cells were seeded into 12 well plates at 30,000 and 100,000 cells/well, respectively. After 24 h,
cells were treated with oleuropein (200 µM) or hydroxytyrosol (100 µM) for 48 h before washing with
PBS and dislodging with 0.25% trypsin EDTA. Cells were diluted to 300 cells/µL prior to staining.
MUSE caspase 3/7 reagent working solution was prepared by diluting the stock solution with 1× PBS.
The MUSE Caspase 7-AAD reagent was diluted with 1× assay Buffer at a ratio of 1:74. Cells were
stained by adding 5 µL of the caspase 3/7 working solution to 50 µL of diluted cells and incubating for
30 min at 37 ◦C and 5% CO2 before adding 150 µL of Caspase 7-AAD working solution and incubating
for 5 mins at room temperature. All assays were performed in triplicate. Fluorescence was read on a
MUSE cell analyser (MERCK Millipore, Sydney, Australia). Results were expressed as percentage of
live cells, early and late apoptotic cells as well as percentage of dead cells.
4.5. Cell Cycle Analysis
The effect of oleuropein on the cell cycle was analysed by DNA staining with propidium iodide
(MERCK Millipore cell cycle kit). MIA PaCa-2 and HPDE cells were seeded into 12 well plates at
30,000 and 100,000 cells/well, respectively. After 24 h, cells were treated with oleuropein (200 µM) or
hydroxytyrosol (100 µM) for 24 h before washing with PBS and dislodging with 0.25% trypsin EDTA.
Cells were washed with PBS before fixing in ice cold 70% ethanol and storing at−20 ◦C for a minimum
of 3 h prior to staining. For staining, cells were centrifuged at 300 g for 5 min, washed in PBS before
resuspending in 200 µL of cell cycle reagent and incubated for 30 min at ambient temperature in the
dark. Fluorescence was read on a MUSE flow cell analyser and DNA content profile histograms were
produced. Results were expressed as percentage of cells in G0/1, S and G2/M phases of the cell cycle.
All assays were performed in triplicate.
4.6. Assessment of the Effect of Oleuropein and Hydroxytyrosol on Gene Expression
HPDE and MIA PaCa-2 cells were seeded into 12 well plates at a concentration of 100,000 or
30,000 cells/well, respectively, and allowed to adhere for 24 h before treatment with either oleuropein
(200 µM), hydroxytyrosol (100 µM) or vehicle control for 24 h. Total RNA was extracted after 18 h
using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) as per the manufacture’s guidelines, with an
overnight −30 ◦C isopropanol and glycogen precipitation. The quantity and integrity of the RNA
preparation was analysed using a 6000 Nano Kit on an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA). RNA integrity number (RIN) integrity scores were all over 7. Total RNA
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(100 ng) was used as starting material. The WT PLUS amplification and labelling process was prepared
according to Affymetrix protocols. Fragmented and biotinylated ss-cDNA preparations (5.5 µg) were
hybridized to HTA 2.0 Arrays, which were subsequently washed, stained, and scanned using a
GeneChip Fluidics station and GeneChip Scanner 3000 (Affymetrix, Carlsbad, CA, USA) according
to the Affymetrix protocol. Array images were processed using the Affymetrix GeneChip command
console (AGCC) to produce probe intensity data (cel files). After using the Expression console to
normalise and examine data quality, only the microarrays meeting acceptable Affymetrix quality
control criteria were considered for further analysis. The Expression console was then used to create
probe level summarisation files (CHP) from the cel files. The Transcriptome analysis console (TAC)
was used to convert the CHP files into a visual representation of the differentially expressed genes.
Statistical analysis was preformed using One-Way ANOVA (unpaired) on genes displaying a significant
fold change [(linear) < −2 or >2, and p-value < 0.05)].
4.7. Protein Expression
HPDE and MIA PaCa-2 cells were seeded into 12 well plates at a concentration of 100,000 or
30,000 cells/well, respectively, and allowed to adhere for 24 h before treatment with either oleuropein
(200 µM), hydroxytyrosol (100 µM) or vehicle control (0.5% DMSO) for 24 h. Whole cell lysates were
collected by lysis with RIPA lysis buffer containing protease inhibitor for 30 min and subsequent
centrifugation at 10,000× g at 4 ◦C for 30 min. Protein concentration was determined by a micro BCA
protein assay kit according to the manufacturer’s instructions (Thermofisher, Mulgrave, Australia).
Lysates were dissolved in sample buffer (0.35 M Tris-HCl pH 6.8, 30% glycerol, 10% SDS and
bromophenol blue) and reducing agent (9% 2-mercaptoethanol) before heating at 75 ◦C for 10 min.
Samples were separated on NuPAGE® Novex® Midi Bis-Tris 4–12% gels followed by transfer onto
nitrocellulose membrane (GE Healthcare, Sydney, Australia). The membranes were blocked using 10%
skim milk in TBST, washed with TBST and probed with primary antibodies for 2 h and secondary
antibodies for 1 h before addition of a chemiluminescent substrate (Luminata Classico western Horse
Radish Peroxidase substrate, MERCK-Millipore, Temecula, MA, USA). Bands were revealed using an
Amersham Imager 600 (GE Healthcare, Sydney, Australia). The following primary antibodies were
used: rabbit polyclonal anti-Bax (dilution 0.125 µg/mL; abc11; MERK Millipore, Burlington, MA, USA),
rabbit monoclonal anti-Bak (dilution 1:1000; 06-536; MERK Millipore), mouse monoclonal anti-Bcl-2
(dilution 2 µg/mL; 05-729: MERK Millipore), rabbit polyclonal anti-ADAMTS1 antibody (dilution 1
µg/mL; ab113847; abcam), rabbit polyclonal anti-c-Fos antibody (dilution 1:500; ab209795; abcam),
rabbit monoclonal anti-c-Jun antibody (dilution 1:2000; (E254) ab32137; abcam), rabbit polyclonal
anti-EGR-1 antibody (dilution 1:500; ab208780; abcam), rabbit polyclonal anti-GAPDH (dilution 1:1000;
00-18231; Biovision, San Fransisco, CA, USA). The secondary antibodies were rabbit anti-goat (dilution
1:5000; 172-1034; BioRad, Hercules, CA, USA), mouse anti-goat (dilution 1:5000; 170-6516; BioRad).
4.8. Statistics
GraphPad Prism Version 7.0 was used to determine the IC50 of normalised and transformed
viability data. Ordinary two-way ANOVA followed by Tukey’s multiple comparisons test was
conducted on cell cycle, caspase 3/7 expression and expression of apoptosis proteins data to compare
treated versus vehicle control cells. Ordinary one-way ANOVA followed by Tukey’s multiple
comparisons test was conducted on Bax/Bcl-2 ratio and gene expression data to compare treated
versus vehicle control cells. Significance was set at p < 0.05.
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